DNA Biomed Solns (DNA) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.003x

Based on the latest financial reports, DNA Biomed Solns (DNA) has a cash flow conversion efficiency ratio of -0.003x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-265.00K ≈ $-710.46 USD) by net assets (ILA82.79 Million ≈ $221.96K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

DNA Biomed Solns - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how DNA Biomed Solns's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does DNA Biomed Solns carry for a breakdown of total debt and financial obligations.

DNA Biomed Solns Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of DNA Biomed Solns ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
DOREL INDS INC. B F:DO4B	0.485x
Atlas Engineered Products Ltd V:AEP	0.050x
FASOO.COM Co Ltd KQ:150900	0.081x
Gediz Ambalaj Sanayi ve Ticaret AS IS:GEDZA	0.012x
Buyung Poetra Sembada Tbk PT JK:HOKI	0.209x
I Yuan Precision Ind Co Ltd TWO:2235	0.006x
MST GOLF GROUP BERHAD KLSE:5316	0.093x
Synel M.L.L Payway Ltd TA:SNEL	-0.065x

Annual Cash Flow Conversion Efficiency for DNA Biomed Solns (2013–2024)

The table below shows the annual cash flow conversion efficiency of DNA Biomed Solns from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of DNA Biomed Solns.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA101.47 Million ≈ $272.02K	ILA1.61 Million ≈ $4.32K	0.016x	+285.32%
2023-12-31	ILA79.19 Million ≈ $212.30K	ILA-678.00K ≈ $-1.82K	-0.009x	-93.75%
2022-12-31	ILA80.11 Million ≈ $214.76K	ILA-354.00K ≈ $-949.06	-0.004x	+89.70%
2021-12-31	ILA54.33 Million ≈ $145.66K	ILA-2.33 Million ≈ $-6.25K	-0.043x	+44.17%
2020-12-31	ILA7.95 Million ≈ $21.32K	ILA-611.00K ≈ $-1.64K	-0.077x	-57.74%
2019-12-31	ILA28.18 Million ≈ $75.56K	ILA-1.37 Million ≈ $-3.68K	-0.049x	-90.35%
2018-12-31	ILA64.90 Million ≈ $174.00K	ILA-1.66 Million ≈ $-4.45K	-0.026x	+7.16%
2017-12-31	ILA69.11 Million ≈ $185.27K	ILA-1.91 Million ≈ $-5.11K	-0.028x	-116.08%
2016-12-31	ILA-83.41 Million ≈ $-223.63K	ILA-14.30 Million ≈ $-38.34K	0.171x	-90.81%
2015-12-31	ILA-8.35 Million ≈ $-22.38K	ILA-15.57 Million ≈ $-41.73K	1.865x	+41.84%
2014-12-31	ILA-8.36 Million ≈ $-22.40K	ILA-10.99 Million ≈ $-29.45K	1.315x	+391.99%
2013-12-31	ILA11.49 Million ≈ $30.80K	ILA-5.17 Million ≈ $-13.87K	-0.450x	--

About DNA Biomed Solns

TA:DNA Israel Biotechnology

Market Cap

$34.04 Million

ILA12.70 Billion ILA

Market Cap Rank

#23386 Global

#332 in Israel

Share Price

ILA103.10

Change (1 day)

-3.64%

52-Week Range

ILA86.50 - ILA147.50

All Time High

ILA1900.80